MedTrace Logo

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

NCT01678430 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 670

Last updated 2012-10-15

No results posted yet for this study

Summary

The purpose of this study is to compare ofatumumab \& chlorambucil (O-Chl) versus ofatumumab \& bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine \& cyclophosphamide (R-FC).

Conditions

Interventions

DRUG

Ofatumumab

DRUG

Chlorambucil

DRUG

Bendamustine

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Napp Pharmaceuticals Limited

    collaborator INDUSTRY

  • Chugai Pharma USA

    collaborator INDUSTRY

  • University of Liverpool

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01678430 on ClinicalTrials.gov